Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Thursday, November 5, 2026

Back to the front page

AppLovin 3Q26 Business Update: No Notes

AppLovin’s Q3 revenue rose 55% year over year as AXON model gains expanded margins, while ad take-rate compression remains the key competitive risk.

APP $118B
Speedwell Research 3 clicks

From X

@aleabitoreddit 2 clicks

Serenity on X

Last time I've seen "It's all over" type posts was... 3 months ago during the situational awareness liquidation. And... 3 months ago before that... with Iran tensions + Oil + Helium + LNG fears/pricing. And... few months ago before that. I'm sure everyone remembers Deepseek back in like 2025 Each one had genuine risks, with rate hikes/margin liquidations to oil prices + supply disruption. And now financing/credit markets. Not trying to downplay the risks but haven't seen it materialize in the companies I'm tracking (eg. optical sector) given counterparty types + sector visibility + architectural shifts in 2027-2028. For example in this $LITE CEO interview, the guy said there hasn't been any order cancellation/delays given rate hikes. But obviously neocloud sector that uses heavy debt leverage might be different. I've seen that the general sentiment was a recovery after midterms in 2 weeks, I'm not the type to give predictions like that. We'll see Directionally bullish on certain sectors of AI supply chain like memory/photonics, but everything was sold off indiscriminately, even if they're not exactly the same trade.
@aleabitoreddit

Serenity on X

I can't give advice on what others should do but from what I'm seeing from $AAOI revenue ramp, it looks something like this from disclosed capacity. -> $858M Q1 2027 -> $1.29B Q2 2027 -> $1.62B Q3 2027 -> $1.89B Q4 2027 -> $2.14B Q1 2028 They're sitting on $6.8B MC right now. I'd be very impressed if they do $7.5B exit annualized revenue run rate in 2027 off 40% gross margins and markets assigned them the same valuation. And judging from $LITE making capacity agreements into 2030-2031... I don't quite think demand stalls out after 2027-2028. Anyway, lot of execution risk obviously, but H1 2027 inflection point is pretty close, so I'm personally waiting.
@aleabitoreddit 3 clicks

Serenity on X

$LITE CEO interview on demand, counterparty + financing risk: - "CFO of $GOOGL came on and reported capex going up Y/Y, we expect hyperscalers for report an increase in capex in earnings. Based on what we see, we see their spend going up." - "The purchase agreements we have, to a large degree, are noncancellable." - The difference between Lumentum and companies like $AVGO, "we are not as dependent on AI datacenter buildout going forward" There's a conversion between electrical products to optical products" creating structural demand. Q: When do you see able to see yourself having more inventory? (catching up to surge in demand) - When we look at demand, there is "no end in sight" TLDR: Financing risk and demand aren't equally distributed across AI supply chains. But markets are just selling everything off together. As for photonics in specific, I said this before, but increasing optical content per XPU + CPO/NPO adoption keeps going up so we'll likely see sector spend go up, even if aggregate capex goes down. There's the usual "no end to demand in sight" commentary, but $LITE does have capacity commitments into 2029 now... and are negotiating for 2030. (with new information that most of which are likely hyperscalers + non-cancellable) So doesn't quite sound like it's all over for the AI trade, especially photonics.

Investor Letters

All letters

Trading Post November 5, 2026

MercadoLibre’s logistics expansion cut margins by 60 basis points, while Mercado Pago grew credit 62% with 7% NPLs.

MELI $77B
Cassandra Unchained 2 clicks

Intel: The CPU Comeback, Discounted

Intel's Q3 2026 results were hit by memory costs and an Israel shutdown, but enterprise AI inference could lift CPU demand as server…

INTC $287B
Monte Independent Investment Research 2 clicks

Problems at Twist Bioscience (TWST)

Twist Bioscience’s $200 rebound followed an Anthropic-linked short squeeze, yet its DNA and protein services face broad competition while…

TWST $8B
Hunterbrook 4 clicks

VSH Earnings Review

Vishay reported record Q3 revenue of $979 million, up 24%, and guided Q4 to about $990 million as rising backlog and margins contrast with…

VSH $3.6B
Cestrian Capital Research 3 clicks

Thursday Tailwinds #13: Nov 5, 2026

Florida marinas are 92% full as boat counts rise and permits constrain new supply, creating pricing power for existing operators such as…

SUI $14B
Trade Ideas Flow 6 clicks
CHWY · long

Chewy INC

Chewy (CHWY) is presented as a long opportunity after a prior 2022 short thesis played out.

CHWY $9.2B
Value Investors Club 5 clicks

New Ideas From The Road

Aurelion Research increased healthcare exposure and sees opportunities in banking and defense, alongside research on Alcoa, Nike, ONON and…

AA $10BNKE $60B
Aurelion Research 4 clicks

Oracle: The Party Is Almost Over

Oracle’s CDS spreads exceed 320 basis points as debt approaches $135 billion and fiscal 2027 capex targets $95 billion, amid heavy reliance…

ORCL $363B
David Desjardins 1 click

Site Centers (NYSE:SITC)

Site Centers' $3 per-share return-of-capital distribution and December delisting leave a discounted liquidation stub, with two properties…

CURB $3.6B
Real Assets, Real Value 5 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 74 of 277

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.